Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe Record History now shows a new revision entry (v3.3.2) and omits the older entry (v3.2.0).SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding operating status notice from the page.SummaryDifference0.5%

- Check42 days agoChange DetectedNew version entry dated 2025-01-15 added to Record History, expanding the version chronology. This reflects the most recent submission and study record update.SummaryDifference0.1%

- Check71 days agoChange DetectedMajor update: publish of a funding-related operating status notice and a new software version (v3.2.0) replacing v3.1.0.SummaryDifference11%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%

- Check93 days agoChange DetectedThe page now shows revision v3.0.2, replacing v3.0.1, and the 'Back to Top' element has been removed.SummaryDifference0.7%

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.